AstraZeneca to launch CRISPR-based cancer research centre

Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Cancer Research UK forms immunotherapy alliance

28 March 2019 Cancer Research UK has formed a multimillion-pound drug discovery alliance with fellow charity LifeArc and Japanese company Ono Pharmaceutical.

Big Pharma

AstraZeneca and Daiichi Sankyo to develop new cancer treatment

2 April 2019 Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.

Americas

CRISPR babies still too risky, warns new report

10 September 2020 Human embryos whose genomes have been edited should not be used to create a pregnancy until it is certain that changes can be made without introducing undesired changes, according to a new report by an influential panel.

More on this story

Biotechnology

Cancer Research UK forms immunotherapy alliance

28 March 2019 Cancer Research UK has formed a multimillion-pound drug discovery alliance with fellow charity LifeArc and Japanese company Ono Pharmaceutical.

Big Pharma

AstraZeneca and Daiichi Sankyo to develop new cancer treatment

Americas

CRISPR babies still too risky, warns new report

More on this story

Biotechnology

Cancer Research UK forms immunotherapy alliance

28 March 2019 Cancer Research UK has formed a multimillion-pound drug discovery alliance with fellow charity LifeArc and Japanese company Ono Pharmaceutical.

Big Pharma

AstraZeneca and Daiichi Sankyo to develop new cancer treatment

Americas

CRISPR babies still too risky, warns new report